ChemoCentryx Stock Price, News & Analysis (NASDAQ:CCXI)

$7.32 -0.03 (-0.41 %)
(As of 11/18/2017 11:11 AM ET)
Previous Close$7.32
Today's Range$7.22 - $7.43
52-Week Range$6.13 - $10.80
Volume42,216 shs
Average Volume87,327 shs
Market Capitalization$356.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54

About ChemoCentryx (NASDAQ:CCXI)

ChemoCentryx logoChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).


Industry, Sector and Symbol:
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Sector: Medical
  • Symbol: NASDAQ:CCXI
  • CUSIP: 16383L10
  • Web: www.chemocentryx.com
Debt:
  • Current Ratio: 2.76%
  • Quick Ratio: 2.76%
Sales & Book Value:
  • Annual Sales: $11.94 million
  • Price / Sales: 29.90
  • Book Value: $0.76 per share
  • Price / Book: 9.63
Profitability:
  • Trailing EPS: ($0.60)
  • Net Income: ($39,960,000.00)
  • Return on Equity: -67.57%
  • Return on Assets: -20.43%
Misc:
  • Employees: 62
  • Outstanding Shares: 48,770,000
 

Frequently Asked Questions for ChemoCentryx (NASDAQ:CCXI)

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) announced its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. View ChemoCentryx's Earnings History.

What are Wall Street analysts saying about ChemoCentryx stock?

Here are some recent quotes from research analysts about ChemoCentryx stock:

  • 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (11/13/2017)
  • 2. Cowen and Company analysts commented, "ChemoCentryx reported Q2 financials, including a net loss of $9.2MM and a June 30." (8/8/2017)

Who are some of ChemoCentryx's key competitors?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the folowing people:

  • Thomas J. Schall Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 55)
  • Susan M. Kanaya, Executive Vice President, Chief Financial and Administrative Officer, Secretary (Age 52)
  • Israel F. Charo M.D., Ph.D., Senior Vice President - Research (Age 65)
  • Markus J. Cappel Ph.D., Chief Business Officer, Treasurer (Age 54)
  • Roger C. Lucas Ph.D., Lead Independent Director (Age 73)
  • Henry A. McKinnell Jr., Ph.D., Director (Age 74)
  • Thomas A. Edwards J.D., Independent Director (Age 57)
  • Joseph M. Feczko M.D., Independent Director (Age 66)
  • Geoffrey M. Parker, Independent Director (Age 52)

Who owns ChemoCentryx stock?

ChemoCentryx's stock is owned by a number of of institutional and retail investors. Top institutional investors include Wasatch Advisors Inc. (4.56%), Iguana Healthcare Management LLC (0.56%), OxFORD Asset Management LLP (0.51%), Strs Ohio (0.18%), Russell Investments Group Ltd. (0.16%) and Los Angeles Capital Management & Equity Research Inc. (0.11%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, James L Tyree, Markus J Cappel, Petrus Bekker, Roger C Lucas, Susan M Kanaya and Thomas A Edwards. View Institutional Ownership Trends for ChemoCentryx.

Who sold ChemoCentryx stock? Who is selling ChemoCentryx stock?

ChemoCentryx's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Wasatch Advisors Inc., Schwab Charles Investment Management Inc. and Keybank National Association OH. Company insiders that have sold ChemoCentryx company stock in the last year include Markus J Cappel, Petrus Bekker and Roger C Lucas. View Insider Buying and Selling for ChemoCentryx.

Who bought ChemoCentryx stock? Who is buying ChemoCentryx stock?

ChemoCentryx's stock was acquired by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP, Los Angeles Capital Management & Equity Research Inc., ING Groep NV, Iguana Healthcare Management LLC, Wells Fargo & Company MN, Strs Ohio and ClariVest Asset Management LLC. Company insiders that have bought ChemoCentryx stock in the last two years include Geoffrey M Parker and Thomas A Edwards. View Insider Buying and Selling for ChemoCentryx.

How do I buy ChemoCentryx stock?

Shares of ChemoCentryx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of ChemoCentryx stock can currently be purchased for approximately $7.32.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $356.97 million and generates $11.94 million in revenue each year. The biopharmaceutical company earns ($39,960,000.00) in net income (profit) each year or ($0.60) on an earnings per share basis. ChemoCentryx employs 62 workers across the globe.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900.


MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for ChemoCentryx (NASDAQ:CCXI)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for ChemoCentryx (NASDAQ:CCXI)

Price Target History for ChemoCentryx (NASDAQ:CCXI)

Analysts' Ratings History for ChemoCentryx (NASDAQ:CCXI)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
2/21/2017JMP SecuritiesInitiated CoverageMkt Outperform -> OutperformN/AView Rating Details
8/9/2016J P Morgan Chase & CoReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for ChemoCentryx (NASDAQ:CCXI)

Earnings by Quarter for ChemoCentryx (NASDAQ:CCXI)

Earnings History by Quarter for ChemoCentryx (NASDAQ CCXI)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.26)($0.13)$8.94 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.17)($0.19)$8.94 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.26)($0.12)$8.23 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.22)($0.16)$4.89 millionViewN/AView Earnings Details
11/7/2016Q3($0.08)($0.15)ViewListenView Earnings Details
5/10/2016Q1($0.27)($0.34)ViewListenView Earnings Details
3/14/2016Q4($0.28)($0.26)ViewN/AView Earnings Details
11/9/2015Q315($0.29)($0.26)ViewListenView Earnings Details
8/6/2015Q215($0.29)($0.28)ViewN/AView Earnings Details
5/6/2015Q115($0.28)($0.28)ViewListenView Earnings Details
3/12/2015Q414($0.28)($0.28)ViewListenView Earnings Details
11/5/2014Q3 2014($0.29)($0.25)ViewN/AView Earnings Details
5/8/2014Q114($0.24)($0.27)$0.38 millionViewN/AView Earnings Details
3/13/2014($0.25)($0.22)$1.37 million$0.73 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.28)($0.23)$1.48 million$1.90 millionViewN/AView Earnings Details
5/13/2013Q1 2013($0.27)($0.28)$2.04 million$1.90 millionViewN/AView Earnings Details
11/13/2012Q312($0.28)$1.44 million$1.13 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ChemoCentryx (NASDAQ:CCXI)
Current Year EPS Consensus Estimate: $-0.67 EPS
Next Year EPS Consensus Estimate: $-1.23 EPS

Dividends

Dividend History for ChemoCentryx (NASDAQ:CCXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ChemoCentryx (NASDAQ CCXI)

Insider Ownership Percentage: 26.20%
Institutional Ownership Percentage: 49.15%
Insider Trades by Quarter for ChemoCentryx (NASDAQ:CCXI)
Insider Trades by Quarter for ChemoCentryx (NASDAQ:CCXI)

Insider Trades by Quarter for ChemoCentryx (NASDAQ CCXI)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/1/2017Roger C LucasDirectorSell2,250$10.07$22,657.50View SEC Filing  
7/13/2017Petrus BekkerInsiderSell76,013$9.95$756,329.35View SEC Filing  
7/12/2017Petrus BekkerInsiderSell30,000$9.98$299,400.00View SEC Filing  
7/11/2017Petrus BekkerInsiderSell30,000$9.78$293,400.00View SEC Filing  
7/10/2017Petrus BekkerInsiderSell19,877$9.30$184,856.10View SEC Filing  
6/30/2017Petrus BekkerInsiderSell65,509$9.17$600,717.53View SEC Filing  
5/1/2017Roger C LucasDirectorSell4,000$7.31$29,240.00View SEC Filing  
1/3/2017Markus J CappelInsiderSell26,821$7.51$201,425.71View SEC Filing  
12/16/2016Petrus BekkerInsiderSell8,712$8.74$76,142.88View SEC Filing  
12/5/2016Petrus BekkerInsiderSell30,000$8.50$255,000.00View SEC Filing  
11/22/2016Petrus BekkerInsiderSell1,250$8.30$10,375.00View SEC Filing  
11/11/2016Petrus BekkerInsiderSell33,332$8.00$266,656.00View SEC Filing  
9/1/2016Roger C LucasDirectorSell4,000$5.07$20,280.00View SEC Filing  
5/23/2016James L TyreeDirectorSell5,544$4.39$24,338.16View SEC Filing  
5/17/2016Thomas A EdwardsDirectorBuy50,000$4.05$202,500.00View SEC Filing  
5/16/2016Thomas A EdwardsDirectorBuy25,000$4.05$101,250.00View SEC Filing  
5/13/2016Geoffrey M ParkerDirectorBuy40,000$4.03$161,200.00View SEC Filing  
1/22/2016Susan M. KanayaCFOSell25,764$4.04$104,086.56View SEC Filing  
1/20/2016Susan M. KanayaCFOSell14,971$4.10$61,381.10View SEC Filing  
1/19/2016Susan M. KanayaCFOSell6,134$4.05$24,842.70View SEC Filing  
1/15/2016Susan M. KanayaCFOSell300$4.00$1,200.00View SEC Filing  
1/11/2016Geoffrey M ParkerDirectorBuy20,000$4.63$92,600.00View SEC Filing  
1/8/2016Susan M. KanayaCFOSell10,224$5.12$52,346.88View SEC Filing  
1/6/2016Susan M. KanayaCFOSell47,607$6.98$332,296.86View SEC Filing  
1/5/2016Susan M. KanayaCFOSell34,341$6.90$236,952.90View SEC Filing  
1/4/2016Susan M. KanayaCFOSell10,490$7.38$77,416.20View SEC Filing  
12/11/2015Geoffrey M ParkerDirectorBuy20,000$7.25$145,000.00View SEC Filing  
11/4/2015Value Fund L P BiotechnologyInsiderSell360,000$7.00$2,520,000.00View SEC Filing  
11/2/2015Value Fund L P BiotechnologyInsiderSell50,000$6.97$348,500.00View SEC Filing  
6/10/2015Bvf Partners L P/IlMajor ShareholderSell955,700$9.00$8,601,300.00View SEC Filing  
5/22/2015Ira KleinDirectorSell10,811$7.44$80,433.84View SEC Filing  
4/1/2015Thomas J SchallCEOSell24,267$7.50$182,002.50View SEC Filing  
3/31/2015Thomas J SchallCEOSell16,540$7.55$124,877.00View SEC Filing  
3/30/2015Thomas J SchallCEOSell1,200$7.51$9,012.00View SEC Filing  
3/24/2015Thomas J SchallCEOSell50,371$7.84$394,908.64View SEC Filing  
3/19/2015Thomas J SchallCEOSell18,146$8.34$151,337.64View SEC Filing  
3/17/2015Thomas J SchallCEOSell31,316$8.55$267,751.80View SEC Filing  
3/9/2015Markus J CappelTreasurerSell34,125$7.81$266,516.25View SEC Filing  
3/4/2015Markus J CappelTreasurerSell40,875$7.98$326,182.50View SEC Filing  
3/3/2015Markus J CappelTreasurerSell5,943$7.81$46,414.83View SEC Filing  
3/2/2015Markus J CappelTreasurerSell14,390$8.13$116,990.70View SEC Filing  
11/18/2014Anne-Marie DuliegeEVPSell4,970$4.71$23,408.70View SEC Filing  
5/1/2014Thomas J SchallCEOSell27,726$5.59$154,988.34View SEC Filing  
4/29/2014Thomas J SchallCEOSell32,274$5.38$173,634.12View SEC Filing  
4/22/2014Markus J CappelTreasurerSell20,962$8.17$171,259.54View SEC Filing  
3/17/2014Thomas J SchallCEOSell20,000$7.25$145,000.00View SEC Filing  
12/6/2013Geoffrey M ParkerDirectorBuy20,000$5.15$103,000.00View SEC Filing  
12/5/2013Bvf Partners L P/IlMajor ShareholderBuy189,800$5.01$950,898.00View SEC Filing  
11/6/2013Bvf Partners L P/IlMajor ShareholderBuy136,066$4.92$669,444.72View SEC Filing  
11/1/2013Bvf Partners L P/IlMajor ShareholderBuy336,225$4.99$1,677,762.75View SEC Filing  
10/9/2013Bvf Partners L P/IlMajor ShareholderBuy1,289,354$5.34$6,885,150.36View SEC Filing  
10/3/2013Bvf Partners L P/IlMajor ShareholderBuy109,425$5.49$600,743.25View SEC Filing  
9/13/2013Bvf Partners L P/IlMajor ShareholderBuy325,635$5.95$1,937,528.25View SEC Filing  
9/13/2013Joseph M FeczkoDirectorBuy10,000$6.03$60,300.00View SEC Filing  
8/13/2013Markus J CappelTreasurerSell5,459$12.90$70,421.10View SEC Filing  
8/7/2013Petrus BekkerSVPSell5,000$13.26$66,300.00View SEC Filing  
8/5/2013Roger C LucasDirectorSell5,000$13.42$67,100.00View SEC Filing  
8/1/2013Markus J CappelTreasurerSell6,250$13.82$86,375.00View SEC Filing  
7/17/2013Markus J CappelTreasurerSell5,459$14.52$79,264.68View SEC Filing  
7/17/2013Petrus BekkerSVPSell10,000$14.54$145,400.00View SEC Filing  
7/16/2013Thomas J SchallCEOSell22,089$14.39$317,860.71View SEC Filing  
7/3/2013Roger C LucasDirectorSell5,000$13.43$67,150.00View SEC Filing  
7/2/2013Markus J CappelTreasurerSell6,250$13.88$86,750.00View SEC Filing  
6/28/2013Susan M KanayaCFOSell36,942$14.31$528,640.02View SEC Filing  
6/27/2013Petrus BekkerSVPSell5,000$14.00$70,000.00View SEC Filing  
6/21/2013Markus J CappelTreasurerSell6,250$13.00$81,250.00View SEC Filing  
6/18/2013Markus J CappelTreasurerSell1,783$12.47$22,234.01View SEC Filing  
6/17/2013Petrus BekkerSVPSell5,000$12.00$60,000.00View SEC Filing  
6/3/2013Roger C LucasDirectorSell5,000$13.32$66,600.00View SEC Filing  
5/30/2013Susan M KanayaCFOSell12,770$14.28$182,355.60View SEC Filing  
5/28/2013Markus J CappelTreasurerSell3,676$14.10$51,831.60View SEC Filing  
5/24/2013Petrus BekkerSVPSell4,800$14.00$67,200.00View SEC Filing  
5/17/2013Petrus BekkerSVPSell15,000$13.97$209,550.00View SEC Filing  
5/15/2013Markus J CappelTreasurerSell15,668$14.08$220,605.44View SEC Filing  
5/15/2013Roger C LucasDirectorSell5,000$14.11$70,550.00View SEC Filing  
5/15/2013Thomas J SchallCEOSell7,600$14.04$106,704.00View SEC Filing  
4/11/2013Markus J CappelTreasurerSell1,500$14.10$21,150.00View SEC Filing  
4/11/2013Petrus BekkerSVPSell3,979$14.03$55,825.37View SEC Filing  
4/11/2013Thomas J SchallCEOSell2,529$14.02$35,456.58View SEC Filing  
3/6/2013Petrus BekkerSVPSell11,502$13.98$160,797.96View SEC Filing  
3/6/2013Thomas J SchallCEOSell5,541$14.01$77,629.41View SEC Filing  
3/4/2013Roger C LucasDirectorSell5,000$13.87$69,350.00View SEC Filing  
2/26/2013Juan C JaenSVPSell22,500$12.23$275,175.00View SEC Filing  
2/22/2013Thomas J SchallCEOSell7,500$12.06$90,450.00View SEC Filing  
2/6/2013Roger C LucasDirectorSell3,857$11.52$44,432.64View SEC Filing  
2/4/2013Juan C JaenSVPSell3,875$11.69$45,298.75View SEC Filing  
1/17/2013Markus J CappelTreasurerSell2,700$11.16$30,132.00View SEC Filing  
11/6/2012Bvf Partners L P/IlMajor ShareholderBuy40,000$12.00$480,000.00View SEC Filing  
10/4/2012Roger C LucasDirectorSell1,893$11.47$21,712.71View SEC Filing  
10/1/2012Susan M KanayaCFOSell3,971$11.89$47,215.19View SEC Filing  
10/1/2012Thomas J SchallCEOSell15,000$11.53$172,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ChemoCentryx (NASDAQ CCXI)

Source:
DateHeadline
ChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare ConferenceChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare Conference
finance.yahoo.com - November 17 at 11:06 AM
Zacks Investment Research Lowers ChemoCentryx, Inc. (CCXI) to HoldZacks Investment Research Lowers ChemoCentryx, Inc. (CCXI) to Hold
www.americanbankingnews.com - November 13 at 6:31 PM
ChemoCentryx, Inc. (CCXI) Stock Rating Upgraded by Zacks Investment ResearchChemoCentryx, Inc. (CCXI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 11 at 8:58 PM
ChemoCentryx, Inc. (CCXI) Downgraded by ValuEngineChemoCentryx, Inc. (CCXI) Downgraded by ValuEngine
www.americanbankingnews.com - November 11 at 7:01 PM
Critical Survey: ChemoCentryx (CCXI) vs. Cardiome Pharma Corporation (CRME)Critical Survey: ChemoCentryx (CCXI) vs. Cardiome Pharma Corporation (CRME)
www.americanbankingnews.com - November 9 at 5:28 PM
ChemoCentryx, Inc. (CCXI) Issues Quarterly  Earnings ResultsChemoCentryx, Inc. (CCXI) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 9 at 12:44 AM
Edited Transcript of CCXI earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of CCXI earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 8 at 8:07 PM
Presentations at ASN Kidney Week 2017 Highlight ChemoCentryx Platform in Treatment of Kidney Diseases ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)Presentations at ASN Kidney Week 2017 Highlight ChemoCentryx Platform in Treatment of Kidney Diseases ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
feeds.benzinga.com - November 3 at 9:14 AM
ChemoCentryx to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 7, 2017ChemoCentryx to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 7, 2017
finance.yahoo.com - November 1 at 5:48 PM
ChemoCentryx, Inc. (CCXI) Lowered to "Sell" at ValuEngineChemoCentryx, Inc. (CCXI) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - October 21 at 10:40 AM
ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : October 20, 2017ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : October 20, 2017
finance.yahoo.com - October 20 at 3:22 PM
ChemoCentryx, Inc. (CCXI) Downgraded by Zacks Investment Research to HoldChemoCentryx, Inc. (CCXI) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - October 16 at 8:44 PM
ETFs with exposure to ChemoCentryx, Inc. : October 16, 2017ETFs with exposure to ChemoCentryx, Inc. : October 16, 2017
finance.yahoo.com - October 16 at 5:49 PM
ChemoCentryx, Inc. (CCXI) Lifted to Buy at Zacks Investment ResearchChemoCentryx, Inc. (CCXI) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - October 10 at 6:30 PM
Head-To-Head Contrast: ChemoCentryx (CCXI) & Its PeersHead-To-Head Contrast: ChemoCentryx (CCXI) & Its Peers
www.americanbankingnews.com - October 7 at 4:10 PM
ETFs with exposure to ChemoCentryx, Inc. : October 5, 2017ETFs with exposure to ChemoCentryx, Inc. : October 5, 2017
finance.yahoo.com - October 5 at 11:42 AM
ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 4 at 12:26 PM
ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : October 3, 2017ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : October 3, 2017
finance.yahoo.com - October 3 at 4:54 PM
All You Need To Know About ChemoCentryx Inc’s (CCXI) RisksAll You Need To Know About ChemoCentryx Inc’s (CCXI) Risks
finance.yahoo.com - October 2 at 8:59 PM
Reviewing ChemoCentryx (CCXI) and Its PeersReviewing ChemoCentryx (CCXI) and Its Peers
www.americanbankingnews.com - September 26 at 2:08 PM
Is There Now An Opportunity In ChemoCentryx Inc (CCXI)?Is There Now An Opportunity In ChemoCentryx Inc (CCXI)?
finance.yahoo.com - September 15 at 10:30 PM
Comparing ChemoCentryx (CCXI) and Its PeersComparing ChemoCentryx (CCXI) and Its Peers
www.americanbankingnews.com - September 14 at 2:22 AM
ChemoCentryx to Present at Three Upcoming Investor ConferencesChemoCentryx to Present at Three Upcoming Investor Conferences
finance.yahoo.com - September 5 at 6:35 PM
ChemoCentryx, Inc. – Value Analysis (NASDAQ:CCXI) : August 21, 2017ChemoCentryx, Inc. – Value Analysis (NASDAQ:CCXI) : August 21, 2017
finance.yahoo.com - August 22 at 10:41 PM
ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : August 10, 2017ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : August 10, 2017
finance.yahoo.com - August 10 at 6:13 PM
ChemoCentryx, Inc. (CCXI) Announces Quarterly  Earnings Results, Misses Expectations By $0.02 EPSChemoCentryx, Inc. (CCXI) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - August 10 at 6:12 PM
Edited Transcript of CCXI earnings conference call or presentation 8-Aug-17 9:00pm GMTEdited Transcript of CCXI earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 5:13 PM
ChemoCentryx reports 2Q lossChemoCentryx reports 2Q loss
finance.yahoo.com - August 9 at 5:12 PM
ChemoCentryx, Inc. (CCXI) Given Hold Rating at Cowen and CompanyChemoCentryx, Inc. (CCXI) Given Hold Rating at Cowen and Company
www.americanbankingnews.com - August 9 at 12:38 AM
ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent HighlightsChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - August 8 at 4:48 PM
Reviewing ChemoCentryx (CCXI) and Auxilium Pharmaceuticals (AUXL)Reviewing ChemoCentryx (CCXI) and Auxilium Pharmaceuticals (AUXL)
www.americanbankingnews.com - August 8 at 7:32 AM
ChemoCentryx, Inc. (NASDAQ:CCXI) Expected to Announce Earnings of -$0.19 Per ShareChemoCentryx, Inc. (NASDAQ:CCXI) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - August 8 at 12:28 AM
VIVUS (VVUS) and ChemoCentryx (NASDAQ:CCXI) Head-To-Head ReviewVIVUS (VVUS) and ChemoCentryx (NASDAQ:CCXI) Head-To-Head Review
www.americanbankingnews.com - August 7 at 9:08 AM
ChemoCentryx, Inc. (CCXI) Director Roger C. Lucas Sells 2,250 SharesChemoCentryx, Inc. (CCXI) Director Roger C. Lucas Sells 2,250 Shares
www.americanbankingnews.com - August 3 at 9:28 PM
ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, 2017ChemoCentryx to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 8, 2017
finance.yahoo.com - July 26 at 5:35 PM
Reviewing Vericel Corporation (VCEL) and ChemoCentryx (CCXI)Reviewing Vericel Corporation (VCEL) and ChemoCentryx (CCXI)
www.americanbankingnews.com - July 26 at 8:53 AM
Insider Selling: ChemoCentryx, Inc. (CCXI) Insider Sells 30,000 Shares of StockInsider Selling: ChemoCentryx, Inc. (CCXI) Insider Sells 30,000 Shares of Stock
www.americanbankingnews.com - July 14 at 8:24 PM
Insider Selling: ChemoCentryx, Inc. (NASDAQ:CCXI) Insider Sells 30,000 Shares of StockInsider Selling: ChemoCentryx, Inc. (NASDAQ:CCXI) Insider Sells 30,000 Shares of Stock
www.americanbankingnews.com - July 14 at 8:24 PM
Insider Selling: ChemoCentryx, Inc. (CCXI) Insider Sells 76,013 Shares of StockInsider Selling: ChemoCentryx, Inc. (CCXI) Insider Sells 76,013 Shares of Stock
www.americanbankingnews.com - July 13 at 10:54 PM
ChemoCentryx (CCXI) Catches Eye: Stock Moves Up 6.4%ChemoCentryx (CCXI) Catches Eye: Stock Moves Up 6.4%
finance.yahoo.com - July 12 at 5:37 PM
ChemoCentryx, Inc. (CCXI) Insider Petrus Bekker Sells 19,877 SharesChemoCentryx, Inc. (CCXI) Insider Petrus Bekker Sells 19,877 Shares
www.americanbankingnews.com - July 10 at 10:58 PM
ChemoCentryx to Present at Two Upcoming Investor ConferencesChemoCentryx to Present at Two Upcoming Investor Conferences
feeds.benzinga.com - May 24 at 9:01 AM
ChemoCentryxs (CCXI) CEO Thomas Schall on Q1 2017 Results - Earnings Call TranscriptChemoCentryx's (CCXI) CEO Thomas Schall on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 2:37 AM
ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial ResultsChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 14 at 9:06 PM
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibiCHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
us.rd.yahoo.com - March 14 at 9:06 PM
CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal OfficersCHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 2 at 9:28 PM
Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal DiseasesVifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases
globenewswire.com - February 14 at 2:53 AM
ChemoCentryx (CCXI) Announces Presentation of Data from ... - StreetInsider.comChemoCentryx (CCXI) Announces Presentation of Data from ... - StreetInsider.com
www.streetinsider.com - January 21 at 9:16 PM
ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq ... - NasdaqChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq ... - Nasdaq
www.nasdaq.com - January 21 at 9:16 PM
ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 InhibitorChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor
www.nasdaq.com - January 20 at 10:20 PM

Social Media

Financials

Chart

ChemoCentryx (NASDAQ CCXI) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.